Refers to additional license grant fees under agreement.

No definition available.

Name:	mgnx_AdditionalLicenseGrantFeesUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Total potential clinical, regulatory and sales milestones company could earn under agreement

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

Total potential pre-clinical milestones company could earn under agreement

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialPreClinicalMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

- Definition

Date on which the Company entered into agreement.

+ References

No definition available.

+ Details

Name:	mgnx_CollaborationAndOtherAgreementEnteredDate
Namespace Prefix:	mgnx_
Data Type:	invest:dateStringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of molecules to be developed and commercialized as per collaboration.

+ References

No definition available.

+ Details

Name:	mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Refers to upfront payment recognition period.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	mgnx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=mgnx_GileadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and Other Agreements, Gilead (Details) - Gilead [Member] $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2013 Molecule	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Collaboration and Other Agreements [Line Items]
Collaboration agreement date		January 2013
Recognized revenue under agreement		$ 0.0	$ 5.5	$ 8.0
Deferred revenue		$ 0.0	0.0
Expected period of development		21 months
Commercialization of molecules \| Molecule	4
License grant fees		$ 7.5
Milestone achieved		0.0	$ 0.0
Maximum [Member]
Collaboration and Other Agreements [Line Items]
Additional Potential Pre-Clinical Milestone Payments Under Agreement		20.0
Additional Potential Clinical, Regulatory And Sales Milestone Payments Under Agreement		$ 247.5